



ELSEVIER

Contraception

Contraception 64 (2001) 397–398

Author index

Volume 64

July–December 2001

- Abrams, L. S., 287
Alvarez, F., 43
Alvarez-Sánchez, F., 363
Anant, M. P., 43
Anderson, R. A., 67
Arce, X. E., 223
Archer, D. F., 383
- Bahamondes, L., 223, 363
Baird, D. T., 29
Ballagh, S., 383
Bancroft, J., 51
Bannemerschult, R., 3, 217
Baohua, K., 77
Bapu, C., 255
Barkfeldt, J., 295
Bass, J. L., 51
Batra, S., 187
Begum, R., 281
Beksinska, M., 333
Beksinska, M. E., 309
Benagiano, G., 275
Berlin, J. A., 125
Bhaduri, A. P., 187
Bhuiyan, S. N., 281
Bijaoui, S., 11
Bilian, X., 107
Biswas, A., 43
Brache, V., 43, 363
- Caceres, E., 319
Callahan, M., 377, 383
Castell-Rodríguez, A., 227
Chany, C. J., II, 67
Cianci, A., 145
Ciotta, L., 145
Cook, L. A., 363
Cox, B., 155
Cravioto, M. C., 227
Creinin, M., 383
Creinin, M. D., 87
Cronin, M., 99, 201
Croxatto, H. B., 369
Cruz-Hinojosa, M. D. L., 227
- d'Arcangues, C., 363
Darney, P., 43
D'Cruz, O. J., 113, 177
Del Castillo, S., 223
- De Leo, V., 145
de Pinho, H., 333
Diao, X. H., 67
Diaz, S., 43, 369
Dieben, T., 295
Doncel, G. F., 93
Dupont, G., 11
Durand, M., 227
Durán-Sánchez, O., 227
Düsterberg, B., 99, 201, 217, 235
- Elstein, M., 243
Endrikat, J., 3, 99, 201, 217, 235
- Falk, G., 23
Falk, L., 23
Fei, G., 193
Ferreira, A. C. P., 353
Fielding, S., 271
Fielding, S. L., 81, 339
Foulon, T., 11
Franceschini, S. A., 353
Frezieres, R., 377
Fuller, L., 271
- Gainer, E., 17, 327
Garg, S., 67
Gerlinger, C., 3, 99, 201, 217, 235
Ghosh, R., 261
Goldberg, E., 93
Goldberg, J. M., 301
Gottlieb, C., 59
Goulard, H., 33
Goyaux, N., 33
Graham, C. A., 51
Grimes, D. A., 139
Gros Lambert, P., 11
- Hanson, U., 23
Hao, G., 301
Hays, M., 363
Hennessy, S., 125
Henzl, M. R., 1
Herreros, C., 369
Hite, R., 3
Ho, P. C., 315
Holler, T., 235
Hua, L., 77
Hua, Y., 363
- Huan, S., 77
- Intharasakda, P., 305
- Jennings, V., 149
Jin, G., 249
Jinying, W., 77
Joesoef, M. R., 169
Jones, H., 345
Junge, W., 217
- Kamboj, V. P., 261
Karundeng, A., 169
Katz, D. F., 393
Khan, M. A., 161
Kinman, J. L., 125
Kiriwat, O., 43
Kitchlu, S., 187
Klaisle, C., 43
Klipping, C., 235
Kolghah, A., 173
- Lai, J.-J., 383
la Marca, A., 145
Laporte, F., 11
Larrea, F., 227
Lasseter, K. C., 287
Lewis, J. S., 169
Lichtenberg, E. S., 345
Lihui, H., 77
Liyang, Z., 107
Lucani, B., 145
Lüdicke, F., 243
Luo, G., 249
- Mahony, M. C., 93
Marcus, S. M., 125
Margolis, D. J., 125
Massai, M. R., 369
Massai, R., 363
Mauck, C., 377, 383
McFadyen, L., 333
Mehrotra, P. K., 187
Mei, W., 77
Méry, C., 17
Miller, A., 319
Milsom, I., 23
Mishell, D. R., Jr, 43
Mishell, D. R., Jr., 143

- Montes, M. B. A., 353
Moo-Young, A. J., 369
Moran, J. S., 169
Morgante, G., 145
Morroni, C., 333
Moussa, A. A., 173
Mqhayi, M., 333
Mueck, A. O., 357
- Nami, R., 145
Natarajan, J., 287
Nivsarkar, M., 255
Noah, M., 217
- Owen, D. H., 393
- Padh, H., 255
Parekh, A., 333
Patel, M., 255
Paul, C., 155
Paul, M., 345
Pavez, M., 43
Payen, N., 11
Peng, W., 193
Perrotti, M., 223
Peters, J. J., 393
Petersen, G., 357
Petraglia, F., 145
Petta, C., 223
Petta, C. A., 363
Phelps, R. H., 339
Potts, M., 275
Pymar, H., 383
Pymar, H. C., 87
- Qin, L. H., 301
Qiusheng, Y., 77
Quinteros, E., 369
- Ranta, S., 43
Raymond, E. G., 227
Rees, H. V., 309
Research Group on Methods for the
Natural Regulation of Fertility,
209
- Reyes, M. V., 369
Robergeau, K., 377
Roland, F., 11
Ruebig, A., 99, 201, 217, 235
Runtupalit, C., 169
Ryan, C. A., 169
- Saker, M. E., 173
Salvaterra, A., 363
Sanders, S. A., 51
Schaff, E., 271
Schaff, E. A., 81, 339
Schechter, J., 43
Schiavon, R., 227
Schmidt, W., 3, 99, 201, 217, 235
Schulte-Wintrop, E., 357
Schulz, K. F., 139
Schwartz, J., 383
Schwartz, J. L., 87
Seeger, H., 357
Sethi, A., 255
Sinai, I., 149
Singh, M. M., 261
Sivin, I., 43
Sjögren, B., 59
Skee, D. M., 287
Skegg, D. C. G., 155
Smit, J., 309, 333
Sneyd, M. J., 155
Spielvogel, H., 319
Spona, J., 243
Srivastava, S., 187
Stanczyk, F. Z., 1
Strom, B. L., 125
Sullivan, H., 243
- Tabares, G., 223
Tagy, A. H. E. I., 173
Taneepanichskul, S., 39, 305
Tang, O. S., 29, 315
Tanprasertkul, C., 39
- Thakur, P. S., 277
Thong, K. J., 29
Thonneau, P., 33
Tieyan, W., 77
Toloi, M. R. T., 353
Tremblay, D., 327
- Uckun, F. M., 113, 177
Ulmann, A., 17, 327
- VandeBerg, J. L., 93
Vermani, K., 67
Virkkunen, A., 295
Vitzthum, V. J., 319
- Walker, K., 271
Waller, D. P., 67
Wallwiener, D., 357
Walsh, T., 377
Wan, L., 43
Wang, S., 249
Waurzyniak, B., 177
Weiner, D. H., 383
Wenhuan, Y., 77
Westhoff, C., 81
Wong, F. A., 287
- Xiao, X., 249
Xin-Lei, C., 193
Xuejun, H., 77
- Yimin, C., 77
Ying, C., 77
Yi-Xun, L., 193
Yongmei, Z., 77
Yuren, L., 77
- Zaneveld, L. J. D., 67
Zepeda, A., 369
Zhao, Q., 249
Zhao-Yuan, H., 193
Zhou, S., 249
Zuma, K., 333

**Subject index**
Volume 64
July–December 2001

- Abortion practices, surgical, 345
Abortion seekers, factors related to sexual coercion, 77
AcidForm, bioadhesive gel, 67
Activated protein C (APC) resistance, effect of OC use, 217
Advantage-S, rheological properties, 393
APC (activated protein C)
Apoptosis, early stage of pregnancy (monkey), 193
- Bacterial vaginosis, effect of IUD use, 169
Bioadhesive gel, acid-buffering formulation, 67
Blastocyst implantation, role of membrane sulphhydryl groups (mouse), 255
Bleeding patterns, non-contracepting women, 319
Blood pressure, effect of ethinylestradiol + gestodene, 145
- Calendar method, natural family planning, 209
Cellulose sulfate, tolerance and acceptability, 377
Cellulose sulfate gel, tolerance study, 377, 383 vaginal microbicide and spermicide, 377, 383
Cervical mucus, effect of estradiol cypionate + DMPA, 363
Chorionic gonadotropin levels, following mifepristone, 271
Clinical study, ethinylestradiol + desogestrel, 201 ethinylestradiol + gestodene, 99, 201 ethinylestradiol + levonorgestrel, 3 ethinylestradiol + norethisterone, 3 Norplant-2 implants, 302
Clinical trials, quinacrine sterilization, 277, 281
Commentary, mifepristone abortion, 271 quinacrine sterilization, 275 use of the name "progestin", 1
Consolidated Standards of Reporting Trials (CONSORT) guideline, 139, 143
Contraceptive gels, rheological properties, 393
Copper T-380, effect on liver function tests, 173
- Depot-medroxyprogesterone acetate (DMPA), effect on liver function tests, 173 effect on weight in users, 223
Desogestrel, effect on lipid metabolism, 295 risk of venous thromboembolism, 125
Discontinuation, effect of OC side effects, 161 injectable contraceptive users, 309 Discontinuation of OC use, effects of sexuality and well-being, 51 DMPA (depot-medroxyprogesterone acetate)
- Effectiveness, TwoDay method, 149
Efficacy, levonorgestrel-only emergency contraception, 17
Emergency contraception, ethinylestradiol + levonorgestrel, 23 knowledge, attitudes and use, 333 levonorgestrel, 17, 227, 327 Multiload Cu-375 SL IUD, 107 South Africa, 333 tolerance and efficacy, 17
Emotional well-being, relationship to OC discontinuation, 51
Endometrial membrane sulphhydryl groups, role in blastocyst implantation (mouse), 255
Estradiol cypionate + DMPA, effect on cervical mucus, 363
Ethinylestradiol + desogestrel, clinical study, 201 effect on hemostatic parameters, 353 effect on lipid parameters, 11
Ethinylestradiol + gestodene, 23-day vs. 21-day regimen, 99, 235 clinical study, 201 effect on blood pressure, 145 effect on hemostatic parameters, 353 effect on ovarian activity, 243 effect on renin-aldosterone levels, 145 metabolic effects, 235
Ethinylestradiol + levonorgestrel, clinical study, 3 effect on APC-resistance, 217 effect of biochemical vasoactive markers, 357 effect on lipid parameters, 11 emergency contraception, 23
Ethinylestradiol + norelgestromin, contraceptive patch, 287 pharmacokinetics, 287
Ethinylestradiol + norethisterone, clinical study, 3 effect on APC-resistance, 217
- Failure of IUD, risk factors, 33
Gel-microemulsions, vaginal spermicides, 113

- Gestodene, risk of venous thromboembolism, 125
Guidelines, Consolidated Standards of Reporting Trials (CONSORT), 139, 143
- Hormostatic parameters,
 Effect of ethinyl estradiol + desogestrel, 353
 Effect of ethinyl estradiol + gestodene, 353
HIV-1 positive women, use of Norplant® implants postpartum, 39
- Immune response to LDH-C₄ (male baboon), 93
Implant contraceptive,
 levonorgestrel, 3 39, 43, 301, 305
 Nestorone, 369
Injectable contraceptive,
 depot medroxyprogesterone acetate, 223, 209
 estradiol cypionate + DMPA, 363
 norethisterone enanthate, 309
Injectable contraceptive users, temporary discontinuation, 309
Intrauterine device (IUD),
 copper T-380, 173
 Multiload CU-375 SL, 107
 TCu 380A, 2123, 369
IUD (intrauterine device)
IUD failure, risk factors, 33
IUD use, prevalence of bacterial vaginosis, 169
- Jadelle® rod implants, levonorgestrel levels during use, 43
- Knowledge, attitudes and use, emergency contraception, 333
- Laser photocoagulation, vas deferens occlusion (rabbit, man), 249
LDH-C₄, male immune response (baboon), 93
Levonorgestrel,
 effect on lipid metabolism, 295
 emergency contraception, 17, 227, 327
 pharmacokinetics, 327
 risk of venous thromboembolism, 124
Levonorgestrel levels, use of Jadelle® rod implants, 43
Lipid metabolism, effect of progestogen-only OCs, 295
Lipid parameters,
 effect of ethinylestradiol + desogestrel, 11
 effect of triphasic ethinylestradiol + desogestrel, 11
Liver function tests,
 effect of DMPA, 173
 effect of oral contraceptives, 173
- Male contraception, testosterone enanthate injections, 59
Male tolerance and acceptability, cellulose sulfate, 377
Mechanisms of action, levonorgestrel in emergency contraception, 227
Medical abortion,
 mifepristone + gemeprost, 29
 mifepristone + misoprostol, 81, 87, 339
 minors, 339
 misoprostol, 315
Menses inducing agents, development (rat, hamster), 187
- Metabolic effects, use of ethinylestradiol + gestodene, 235
Microbicide, cellulose sulfate, 383
Mifepristone, monitoring chorionic gonadotropin levels, 271
Mifepristone + gemeprost, second trimester medical abortion, 29
Mifepristone + misoprostol,
 medical abortion, 81
 minors, 339
 same day administration for medical abortion, 87
Minors, medical abortions, 339
Misoprostol,
 medical abortion, 315
 oral vs. vaginal route, 81
Multiload Cu-375 SL IUD, use for emergency contraception, 107
- Natural family planning,
 calendar methods, 209
 TwoDay method, 149
Nestorone implant, use in postpartum women, 369
Non-contracepting women, bleeding patterns, 319
Nonsteroidal chemical agents, pregnancy interceptive activity (rat, hamster), 187
Normal bleeding patterns, non-contracepting women, 319
Norplant® implants,
 use in HIV-1 positive women, 39
 use in older women, 305
Norplant-2® implants, clinical study, 301
- OC (oral contraceptive)
Older women, use of Norplant implants, 305
Oral contraceptive (OC),
 desogestrel, 295
 discontinuation, 161
 effect on liver function tests, 173
 ethinylestradiol + desogestrel, 11, 201, 353
 ethinylestradiol + gestodene, 99, 145, 201, 235, 243, 353
 ethinylestradiol + levonorgestrel, 3, 217, 357
 ethinylestradiol + norethisterone, 3, 217
 levonorgestrel, 295
 side effects, 161
 triphasic ethinylestradiol + levonorgestrel, 11
Oral contraceptive use, predictors of discontinuation, 31
dl-Ormeloxifene activities, effect of tetracycline (rat), 261
Ovarian activity, effect of ethinylestradiol + gestodene, 243
- Patch contraceptive, ethinylestradiol + norelgestromin, 287
Periodic abstinence, natural family planning, 209
Pharmacokinetics,
 ethinylestradiol + norelgestromin patch, 287
 levonorgestrel, 327
Postpartum women, use of Nestorone implants, 369
Pregnancy, role of apoptosis (monkey), 193
Prevalence, vasectomy in New Zealand, 155
Progestin, use of the name, 1
Progestogen-only OCs, effect on lipid metabolism, 295

- Psychosexual aspects, testosterone contraception, 59
- Quinacrine sterilization, 275, 277, 281
- Renin-aldosterone levels, effect of ethinylestradiol + gestodene, 145
- Replens, rheological properties, 393
- Rheological properties, contraceptive gels, 393
- Risk factors, IUD failure, 33
- Risk of new unintended pregnancies, following emergency contraception, 23
- Second trimester medical abortion, mifepristone + gemeprost, 29
- Sexual coercion, relevant factors among abortion seekers, 77
- Sexuality, relationship to OC discontinuation, 51
- Side effects, effects on OC discontinuation, 161
- Spermicidal gel-microemulsions, 113
- Spermicide,
 cellulose sulfate, 383
 vanadocene dithiocarbamate (mouse), 177
- Sterilization, quinacrine, 275, 277, 281
- Sublingual misoprostol, medical abortion, 315
- Sulphydryl groups, role in blastocyst implantation (mouse), 255
- Surgical abortion practices, survey, 345
- Survey, surgical abortion practices, 345
- TCu 380A,
 effect on weight in users, 223
 use in postpartum women, 369
- Temporary discontinuation, injectable contraceptives users, 309
- Testis-specific LDH-C₄, immune response (baboon), 93
- Testosterone enanthate, male contraception, 59
- Tetracycline, effect of dl-ormeloxifene activities (rat), 261
- Tolerance,
 cellulose sulfate, 377
 levonorgestrel-only emergency contraception, 17
- Tolerance study, cellulose sulfate gel, 383
- TwoDay method, effectiveness, 149
- Vaginal bleeding patterns, relationship to fecundity and fetal loss, 319
- Vaginal delivery system, AcidForm bioadhesive gel, 67
- Vaginal delivery vehicle, gel-microemulsions, 113
- Vanadocene dithiocarbamate, toxicity study of spermicide (mouse), 177
- Vas deferens occlusion, laser photocoagulation (rabbit, man), 249
- Vasectomy, prevalence in New Zealand, 155
- Vasoactive markers, effect of ethinyl estradiol + levonorgestrel, 357
- Venous thromboembolism risk, oral contraceptives, 125
- Weight,
 effect of DMPA use, 223
 effect of TCu 380A use, 223



